z-logo
Premium
Cefuroxime axetil versus placebo for children with acute respiratory infection and imaging evidence of sinusitis: A randomized, controlled trial
Author(s) -
Kristo Aila,
Uhari Matti,
Luotonen Jukka,
Ilkko Eero,
Koivunen Petri,
Alho OlliPekka
Publication year - 2005
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2005.tb02076.x
Subject(s) - medicine , cefuroxime , sinusitis , placebo , randomized controlled trial , anesthesia , intensive care medicine , surgery , antibiotics , pathology , microbiology and biotechnology , biology , alternative medicine
Aim: To evaluate the efficacy of antibiotic treatment in children who presented in medical care with respiratory infection and had imaging evidence of sinusitis. Methods: Eighty‐two children (4–10 y) with acute respiratory symptoms and ultrasonography findings suggestive of acute rhinosinusitis were enrolled in a randomized, double‐blind trial. The sinus findings were confirmed with plain radiographs. The children received either cefuroxime axetil in 125‐mg capsules twice a day for 10 d or placebo. Main outcome measures were complete cure in 2 wk and absence of prolonged symptoms or complications. Results: A total of 72 children (88%) completed follow‐up. The sinusitis findings in the ultrasound could be confirmed with plain radiographs in 65 of the 72 patients (90%). The proportion of children completely cured by day 14 was similar in both groups (difference 6%, 95% confidence interval −16% to 29%). Similarly, there was no significant difference in the proportions of children who escaped prolonged disease and complications between the groups (difference 7%, −9% to 24%). Conclusion: A 10‐d course of cefuroxime axetil offered no clinical benefit to children with an acute respiratory illness and imaging evidence of acute sinusitis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here